EuBiologics유바이오로직스
206650 · KOSDAQ · ₩206650 · 유바이오로직스
₩7,460▲ ₩130 (1.77%)End-of-day · Oct 26, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 58.7% | 57.8% | 58.3% | 48.5% | 44.6% | 38.5% |
| Operating margin | 35.4% | 40.7% | 35.7% | 12.8% | −3.1% | −18.7% |
| Net margin | 23.7% | 27.7% | 19.8% | −19.2% | −4.1% | −80.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −18.0% | +55.4% | +40.0% | +24.5% | +39.9% | — |
| Operating income growth | −28.7% | +76.8% | +290.7% | +620.1% | +77.0% | — |
| Net income growth | −29.7% | +117.3% | +244.3% | −476.9% | +92.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 16.3% | 26.8% | 16.0% | −11.7% | −1.9% | −27.5% |
| Return on assets | 12.1% | 18.7% | 10.7% | −8.4% | −1.5% | −21.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 31.7% | 37.0% | 53.1% | 43.2% | 35.4% | 28.8% |
| Net debt to equity | −27.1% | −42.5% | −22.2% | 0.8% | 1.4% | 7.4% |
| Current ratio | 397.4% | 328.5% | 193.2% | 167.6% | 168.6% | 297.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: EuBiologics / 유바이오로직스 / 206650 / KRX:206650
Source: KRX statistical information